|
Jul 18
|
The S&P 500 and Nasdaq Are Joined By These Stocks Hitting New Highs
|
|
Jul 16
|
Looming Tariffs Don't Scare This Swiss Cancer Treatment Stock
|
|
Jul 16
|
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
|
|
Jun 28
|
BeOne Medicines price target raised to $330 from $313 at Morgan Stanley
|
|
Jun 26
|
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
|
|
Jun 25
|
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
|
|
Jun 24
|
Exploring US High Growth Tech Stocks To Watch In June 2025
|
|
Jun 12
|
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
|
|
Jun 11
|
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
|
|
Jun 11
|
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
|
|
May 31
|
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
|
|
May 27
|
Sector Update: Health Care Stocks Rise Premarket Tuesday
|
|
May 27
|
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
|
|
May 27
|
BeiGene Says EU Panel Recommends Tevimbra as Treatment for Nasopharyngeal Cancer
|
|
May 27
|
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
|
|
May 22
|
Exploring US High Growth Tech Stocks In May 2025
|
|
May 22
|
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
|
|
Apr 17
|
BeiGene to Announce First Quarter 2025 Financial Results on May 7
|
|
Apr 3
|
BeiGene halts ociperlimab amid poor Phase III trial predictions
|
|
Apr 3
|
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
|